CDK4/6 Inhibitors in Early-stage Breast Cancer
A mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
A mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
Surgical oncologist Samilia Obeng-Gyasi describes research that shows chronic stress is associated with higher mortality in cancer.
The FDA will review a blood test that detects colon cancer, and a writer recounts his sister’s decision to receive medical aid in dying.
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer screening method.
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
SABCS panel describes advances and pivotal questions in managing patients whose breast cancer has metastasized to their brain.
“What will you do Monday morning?” was the question posed by the final session on the final full day of the 2023 San Antonio Breast Cancer Symposium (SABCS), held Tuesday, December 5 to Saturday,...
Progression-free survival among certain patients with metastatic colorectal cancer continued at a high level after immune checkpoint inhibitor therapy was stopped. Some patients with metastatic colorectal cancer who benefit from immunotherapy are reluctant to...
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for the treatment of patients with locally advanced or...